Cancer Theranostics - Potential Applications of Cancer Biomarker Database

http://www.sciclips.com/sciclips/blogArticle.do?id=1017&blog=Cancer...

Home

About SciClips

Contact Us

Register

Login

Upload Videos

Open Innovation Platform for Scientific Breakthroughs, Collaborations and Philanthropism Open Innovation Sciclips Direct Bioassay Kits Bioprotocols Share Reagents Video Protocols Open Collaboration Drug Targets Biomarkers Blog

Stem Cell Research | Proteomics / Biomarkers / Metabolomics | Drug Discovery | Biofuels | Tuberculosis | Mosquito-Borne Diseases

Cancer Theranostics - Potential Applications of Cancer Biomarker Database

Sun, January 08 2012, 12:00 AM Posted By: Sclclips

Visit our section on

Most Cited Reagents

Visit our section on

Availability of a comprehensive cancer biomarker database may opens up scientific and technical opportunities in developing innovative oncologic theranostics (Rx/Dx), a diagnostic therapy process that leads to the development of successful personalized medicine strategies in cancer treatment. With the growing trend towards the advancement of personalized medicine concept, there is a need to develop strategies and tools that can be used for individualized diagnosis and treatment. Theranostics based tools, a combination of diagnostics and therapeutics approach, offer promising agents that can be used for the improved diagnosis and treatment of various diseases. In oncologic theranostics, developing innovative personalized cancer treatment rely on the identification of novel cancer biomarkers and diagnostic assays to identify patient s response to a particular drug, for optimizing personalized drug treatment regimen (drug dose, drug treatment schedule etc) and for monitoring the efficacy of treatment (disease stage, tumor progression, tumor recurrence etc). A best example for this will be the approval of Genentech's Herceptin with DakoCytomation's HercepTest for breast cancer theranostics. Future development of cancer theranostic tools depends on the discovery and validation of existing or novel cancer biomarkers. A database that contains comprehensive information on discovery phase or clinically validated biomarkers, along with therapeutic drug target information, can be a powerful tool in developing novel theranostic assays as well as for the discovery of new drug targets based on theranostics (Fig.1). A combination of therapeutic drug target and biomarker pathway analysis, in particular companion diagnostics pathways, can pave the path towards developing innovative strategies in cancer theranostics.

Bioprotocols

www.twitter.com/sciclips

All Open Innovation Legal and Ethics Stem Cells Proteomics Drug Discovery

On Wed, January 25 2012, 04:17 PM Sciclips commented on Cancer Theranostics Potential Applications of Cancer Biomarker Database "Please join the following

discussion group:
LinkedIn Theranostics group " On Tue, January 24 2012, 07:10 PM Sciclips commented on Cell Based Reporter Assays vs. Animal Studies in Drug Discovery- Potential Limitations, Risks and Liabilities

"Additional comments on this topic can be seen at Linkedin Nuclear Receptor Resource group (open group):
On Thu, January 19 2012, 04:22 AM Harish commented on Cancer Theranostics Potential Applications of Cancer Biomarker Database "Nice article, very usefull" On Tue, January 17 2012, 07:27 PM Sciclips commented on Cell Based Reporter Assays vs. Animal Studies in Drug Discovery- Potential Limitations, Risks and Liabilities "We are

Fig. 1: Theranostics and cancer biomarker database in personalized medicine Biomarkers that have potential applications in cancer theranostics can be broadly classified into: 1. Imaging biomarkers: Drug molecules labeled with imaging tags (e.g. NRI, MRI etc.) and antigen-directed imaging drugs (e.g. radiolabeled antibody drugs) are the very good examples. In this case, a single molecule can be used as a diagnostic and therapeutic agent, EGFR, VEGF and TAG-72 are very good

trying to identify and create a list of technologies or products related to drug discovery/development assays, which do not involve genetic manipulation of cells or reporter genes/proteins or m..."

1 of 3

1/27/2012 12:44 PM

Cancer Theranostics - Potential Applications of Cancer Biomarker Database

http://www.sciclips.com/sciclips/blogArticle.do?id=1017&blog=Cancer...

2.

3.

4.

5.

6.

examples where antibodies against these drug targets tagged with imaging markers can be used in theranostics. Imaging biomarkers can also be very useful in targeted surgical treatment of cancer. Labeled antibody based detection of phosphorylated or dephosphorylated will be an attractive theranostics tool in phosphorylation-dependent targeted cancer therapy and diagnosis. Epigenetic biomarkers are another attractive target for developing cancer theranostics. Applications of additional tools such as nanoparticles and gold particles have been demonstrated in theranostics. Diagnostic/prognostic protein biomarkers: Immunohisotchemistry and immunoassays (e.g. ELISA) can be used in theranostic applications. Identification of diagnostic biomarkers that can be used as therapeutic drug targets will have significant impact in theranostics. Development of protein biomarker-directed antibodies (labeled) or small molecules or aptamers can be a potential theranostics tool. Molecular diagnostic markers (genes/SNPs/miRNA/epigenetic): PCR, qPCR, DNA sequencing (including next generation sequencing), and microarray based technologies can be used as theranostics tools. Single step diagnostic therapy, like labeled antibody drug based theranostics, may be a challenging task with molecular diagnostic biomarkers, possible exceptions are siRNA or miRNA based cancer therapies. Cell based biomarkers: Cancer stem cells, circulating tumor cells (CTCs) and tumor-infiltrating immune cells (CD68-positive macrophages/T-cells etc.) can be used in cancer theranostics. The diagnostic and therapeutic significance of these cell based biomarkers have been demonstrated in several published studies. Drug efficacy/response/predictive biomarkers: Biomarkers include proteins, gene, miRNA, SNPs, metabolites etc., which can be successfully used for the development of companion diagnostic assays. These biomarkers can also become a therapeutic drug target for further discovery of theranostics based therapeutic drug targets. Combination therapy response biomarkers: Combination therapy approaches have been demonstrated as an efficient treatment method for various cancers. However, the availability of companion therapy response biomarkers are limited (some of these biomarkers are included in our cancer biomarker database). Wide adoption of combination therapy as a method for cancer treatment may warrants a need for the discovery and validation of new biomarkers associated with combination therapy.

On Tue, January 17 2012, 07:54 AM rnc123 commented on Cell Based Reporter Assays vs. Animal Studies in Drug Discovery- Potential Limitations, Risks and Liabilities "It is also

interesting to point out that transfection reagents used in creating cell based reporters can also have an impact genetic and protein functions in cells. Citations: 1. Transcriptional eff..."
On Tue, November 08 2011, 04:30 PM Dutch commented on "Idea stealing"- does it affect scientific innovation and creativity? "I'll

second T Johnson as I am basically trying to make the same point. Most of the ideas "stolen" are application based and not truly original ideas. Very few people ever have true, revolutionary co..."
On Tue, September 27 2011, 11:30 PM DMPK commented on "Idea stealing"- does it affect scientific innovation and creativity?

Identification of new biomarkers and availability of large number biomarkers may result in the development of theranostics for most of the cancer types. A cancer biomarker database that contains comprehensive and cumulative information on experimental and clinically validated biomarkers, especially companion diagnostic biomarkers and therapeutically relevant biomarkers, may opens up scientific and technical opportunities in developing innovative oncologic theranostics (Rx/Dx) tools. Sciclips cancer biomarker database contains more than 8700 cancer biomarkers, which are classified into 1) diagnostic biomarkers 2) disease predictive/risk assessment biomarkers 3) drug efficacy/response biomarkers 4) prognostic biomarkers and 5) cancer companion diagnostics biomarker pathway. The biological and molecular functions, biological process associated, chromosomal location, SNPs and protein-protein interaction networks of each biomarker are listed in this database. This comprehensive information will be useful for the validation of existing biomarkers and for the identification and validation of new biomarkers for cancer theranostics. Please follow the link to see the details of cancer biomarker database: http://www.sciclips.com/sciclips/diagnostic-prognostic-cancer-biomarker-main.do

"Stealing ideas is ofcourse the best example of bankruptcy of the boss, it is because no attention is paid about the suitability of the person for the position due to favoritism. The boss can be duffe..."
On Tue, September 20 2011, 07:33 AM Sciclips commented on "Idea stealing"- does it affect scientific innovation and creativity?

"Please see a very interesting comment on this blog topic in Cafepharma discussion forum: http://www.cafepharma.com/boards /showthread.php?p=4066217"
On Fri, August 26 2011, 10:09 AM Sciclips commented on Cell based reporter assays: misleading approach in drug discovery? "See

the comments in Wordpress: http://sciclips.wordpress.com /2010/10/25/cell-based-reporterassays-misleading-approach-in-drugdiscovery/"

On Fri, August 26 2011, 10:07 AM Sciclips commented on Are large protein fusion tag based technologies, including protein arrays, truly useful in functional proteomics or systems biology or drug discovery research?

Categories: Biomarkers

"See the comments in Wordpress: http://tinyurl.com/29oqhpc" Post a comment

Cell Based Reporter Assays vs. Animal Studies in Drug Discovery- Potential Limitations, Risks and Liabilities
Posted on Sun, January 15 2012, 12:00 AM

Choose an identity Sciclips Account User name: Password : Anonymous

Cancer Theranostics - Potential Applications of Cancer Biomarker Database Posted on Sun, January 08 2012,
12:00 AM

"Idea stealing"- does it affect scientific innovation and creativity?

Posted on Thu, August 18 2011, 12:00 AM

Enter challenge text as seen on the right: Post Your Comment

Is it too early to brand biomarker discovery as a "Hype"? Posted on Mon,

August 01 2011, 12:00 AM

2 of 3

1/27/2012 12:44 PM

Cancer Theranostics - Potential Applications of Cancer Biomarker Database

http://www.sciclips.com/sciclips/blogArticle.do?id=1017&blog=Cancer...

Sciclips said Please join the following discussion group: LinkedIn Theranostics group
Posted on Wed, January 25 2012, 04:17 PM

Are stem cells ready as a next generation drug discovery tool? Posted
on Mon, December 20 2010, 12:00 AM

Harish said Nice article, very usefull

Posted on Thu, January 19 2012, 04:22 AM

Cell based reporter assays: misleading approach in drug discovery? Posted on Mon, October 25
2010, 12:00 AM

Are large protein fusion tag based technologies, including protein arrays, truly useful in functional proteomics or systems biology or drug discovery research? Posted on Tue,
October 05 2010, 12:00 AM

Stem Cell Research Reagents: Future Perspectives Posted on Sun, June 20 2010,
12:00 AM

Are current cell-based assays truly reliable for drug screening? Posted on
Sun, December 06 2009, 12:00 AM

Is Cancer Stem Cell the "Messiah of Cancer Cure"? Posted on Sun, October 18
2009, 12:00 AM

SciClips LLC, 1202 Ann Street, Madison, WI 53713 USA; contact@sciclips.com All Rights Reserved 2009-2012

3 of 3

1/27/2012 12:44 PM